$1.25 Million in Sales Expected for Crispr Therapeutics AG (CRSP) This Quarter

Wall Street brokerages forecast that Crispr Therapeutics AG (NASDAQ:CRSP) will announce sales of $1.25 million for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Crispr Therapeutics’ earnings. The highest sales estimate is $2.00 million and the lowest is $500,000.00. Crispr Therapeutics reported sales of $1.36 million during the same quarter last year, which would suggest a negative year-over-year growth rate of 8.1%. The business is expected to issue its next quarterly earnings report on Tuesday, May 14th.

On average, analysts expect that Crispr Therapeutics will report full year sales of $25.82 million for the current fiscal year, with estimates ranging from $4.00 million to $91.10 million. For the next year, analysts expect that the company will report sales of $42.43 million, with estimates ranging from $8.00 million to $109.30 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that follow Crispr Therapeutics.

Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Monday, February 25th. The company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.09). The company had revenue of $0.10 million during the quarter, compared to analyst estimates of $1.56 million. Crispr Therapeutics had a negative net margin of 5,281.08% and a negative return on equity of 48.35%. Crispr Therapeutics’s revenue for the quarter was down 99.7% compared to the same quarter last year.

Several equities research analysts have recently weighed in on the company. Zacks Investment Research raised Crispr Therapeutics from a “hold” rating to a “buy” rating and set a $40.00 price target for the company in a research note on Friday, March 1st. BidaskClub lowered Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, March 22nd. William Blair began coverage on Crispr Therapeutics in a research report on Wednesday, March 13th. They set a “market perform” rating on the stock. SunTrust Banks restated a “buy” rating on shares of Crispr Therapeutics in a research report on Monday, December 31st. Finally, Needham & Company LLC began coverage on Crispr Therapeutics in a research report on Sunday, December 9th. They set a “buy” rating and a $38.72 target price on the stock. Three equities research analysts have rated the stock with a sell rating, five have given a hold rating and six have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $45.75.

Shares of CRSP stock traded up $0.79 on Wednesday, hitting $35.72. The company had a trading volume of 444,861 shares, compared to its average volume of 760,790. The stock has a market cap of $1.83 billion, a price-to-earnings ratio of -10.38 and a beta of 3.13. Crispr Therapeutics has a twelve month low of $22.22 and a twelve month high of $73.90.

In other news, President Rodger Novak sold 85,220 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $40.40, for a total value of $3,442,888.00. Following the transaction, the president now owns 1,024,534 shares in the company, valued at $41,391,173.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 126,003 shares of company stock worth $4,989,303 in the last 90 days. Corporate insiders own 37.70% of the company’s stock.

Hedge funds have recently bought and sold shares of the company. Ontario Teachers Pension Plan Board purchased a new stake in shares of Crispr Therapeutics during the fourth quarter valued at approximately $16,598,000. EcoR1 Capital LLC purchased a new stake in shares of Crispr Therapeutics during the third quarter valued at approximately $22,175,000. Credit Suisse AG increased its position in shares of Crispr Therapeutics by 56.0% during the third quarter. Credit Suisse AG now owns 596,052 shares of the company’s stock valued at $26,435,000 after acquiring an additional 213,988 shares during the last quarter. Laurion Capital Management LP purchased a new stake in shares of Crispr Therapeutics during the third quarter valued at approximately $7,660,000. Finally, Capital International Investors purchased a new stake in shares of Crispr Therapeutics during the third quarter valued at approximately $6,120,000. Institutional investors own 42.23% of the company’s stock.

Crispr Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.

Featured Article: How to interpret a stock’s beta number

Get a free copy of the Zacks research report on Crispr Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.